People who have a potentially dangerous reaction to heparin or heparin-like drugs (a condition called heparin-induced thrombocytopenia, or HIT) may benefit from argatroban. However, make sure to review information on this medication's safety issues before beginning treatment, as argatroban should not be given to people with certain medical conditions or those who are taking certain medicines.
Argatroban is approved to prevent or treat blood clots in people with HIT. It is also licensed for use in people who have HIT or are at risk for HIT and have to undergo an angioplasty procedure. Although argatroban does not break down blood clots, it can help slow down their formation to allow the body more time to break them down naturally.
Argatroban is administered intravenously (by an "IV drip") by a healthcare provider in a healthcare setting. Possible side effects include chest pain, diarrhea, and bleeding.
(For more information on this medication, click Argatroban. This article offers a complete overview on this medicine, including how it works, details on safety and effectiveness, and dosing guidelines.)
Written by/reviewed by: Arthur Schoenstadt, MD
Last reviewed by: ArthurSchoenstadt, MD
List of references (click here):
Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2009 March.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed January 4, 2012.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click